Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

EGFR tyrosine kinase inhibitor (TKI) vs observation

Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.99 [0.81, 1.2]
1 study · 835 participants
Low

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Overall survival · treatment of relapsed epithelial ovarian cancer

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.25 [0.8, 1.95]
1 study · 129 participants
Low